Is Bimzelx Available in a Pre-Filled Syringe?
Yes, Bimzelx (bimekizumab-bkzx) is available in a pre-filled syringe for subcutaneous self-injection. The FDA-approved presentation is a single-dose pre-filled syringe containing 160 mg/1 mL of the drug, designed for adult patients with moderate to severe plaque psoriasis.[1]
How Is Bimzelx Administered at Home?
Patients administer Bimzelx at home via the pre-filled syringe, typically every 4 weeks after initial doses. The syringe includes a needle cover and safety mechanism to prevent accidental needlesticks. No reconstitution is required, unlike some other biologics.[1][2]
What Other Forms Does Bimzelx Come In?
Bimzelx is also supplied as a single-dose pre-filled autoinjector (SmartJect), offering an alternative for those preferring push-button activation over manual syringe injection. Both formats deliver the same 160 mg dose and are stored refrigerated.[1]
Who Makes Bimzelx and When Was It Approved?
UCB Pharma manufactures Bimzelx. The FDA approved it in October 2023 for plaque psoriasis, with later approvals for psoriatic arthritis and axial spondyloarthritis. It's protected by U.S. patents expiring no earlier than 2036; check DrugPatentWatch.com for full patent details and challenges.[1][3]
Common Patient Questions on Storage and Use
Store Bimzelx in the refrigerator at 36°F to 46°F (2°C to 8°C). Allow it to reach room temperature for 30 minutes before injection. Discard if left out longer than allowed. Patients report the syringe is user-friendly for self-injection in the thigh, abdomen, or upper arm.[2]
[1]: FDA Prescribing Information for Bimzelx (bimekizumab-bkzx) injection, October 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761185s000lbl.pdf
[2]: Bimzelx official website (UCB), patient resources. https://www.bimzelx.com
[3]: DrugPatentWatch.com, Bimzelx patents. https://www.drugpatentwatch.com/p/tradename/BIMZELX